Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) Insider Sells 3,932 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider now directly owns 6,068 shares in the company, valued at $218,083.92. The trade was a 39.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

CRISPR Therapeutics Trading Up 2.9%

Shares of CRSP traded up $1.09 during trading hours on Tuesday, reaching $38.04. The stock had a trading volume of 1,837,059 shares, compared to its average volume of 1,713,825. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The firm has a 50-day simple moving average of $36.54 and a 200 day simple moving average of $41.29. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -8.70 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The company's quarterly revenue was up 71.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.43) earnings per share. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. Citigroup lowered their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. Truist Financial boosted their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, May 20th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $71.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. SVB Wealth LLC bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth $25,000. Wood Tarver Financial Group LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth $30,000. Costello Asset Management INC bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth $27,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth $36,000. Finally, Western Pacific Wealth Management LP grew its stake in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the period. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.